An autoantibody profile identified by human genome-wide protein arrays in rheumatoid arthritis

Abstract

Precise diagnostic biomarkers of anticitrullination protein antibody (ACPA)-negative and early-stage RA are still to be improved. We aimed to screen autoantibodies in ACPA-negative patients and evaluated their diagnostic performance. The human genome-wide protein arrays (HuProt arrays) were used to define specific autoantibodies from the sera of 182 RA patients and 261 disease and healthy controls. Statistical analysis was performed with SPSS 17.0. In Phase I study, 51 out of 19,275 recombinant proteins covering the whole human genome were selected. In Phase II validation study, anti-ANAPC15 (anaphase promoting complex subunit 15) exhibited 41.8% sensitivity and 91.5% specificity among total RA patients. There were five autoantibodies increased in ACPA-negative RA, including anti-ANAPC15, anti-LSP1, anti-APBB1, anti-parathymosin, and anti-UBL7. Anti-parathymosin showed the highest prevalence of 46.2% (p = 0.016) in ACPA-negative early stage (<2 years) RA. To further improve the diagnostic efficacy, a prediction model was constructed with 44 autoantibodies. With increased threshold for RA calling, the specificity of the model is 90.8%, while the sensitivity is 66.1% (87.8% in ACPA-positive RA and 23.8% in ACPA-negative RA) in independent testing patients. Therefore, HuProt arrays identified RA-associated autoantibodies that might become possible diagnostic markers, especially in early stage ACPA-negative RA.

Keywords

anticitrullination protein antibody (ACPA) / autoantibody / HuProt array / rheumatoid arthritis

References

[1] Harnden K, Pease C, Jackson A. Rheumatoid arthritis. BMJ. 2016; 352: i387.

[2] Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998; 101: 273-281.

[3] Wu X, Liu Y, Jin S, et al. Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nat Commun. 2021; 12: 4977.

[4] Nakken B, Papp G, Bosnes V, et al. Biomarkers for rheumatoid arthritis: from molecular processes to diagnostic applications-current concepts and future perspectives. Immunol Lett. 2017; 189: 13-18.

[5] Dotzlaw H, Schulz M, Eggert M, Neeck G. A pattern of protein expression in peripheral blood mononuclear cells distinguishes rheumatoid arthritis patients from healthy individuals. Biochim Biophys Acta. 2004; 1696: 121-129.

[6] Tabushi Y, Nakanishi T, Takeuchi T, et al. Detection of citrullinated proteins in synovial fluids derived from patients with rheumatoid arthritis by proteomics-based analysis. Ann Clin Biochem. 2008; 45: 413-417.

[7] Noh R, Park SG, Ju JH, et al. Comparative proteomic analyses of synovial fluids and serums from rheumatoid arthritis patients. J Microbiol Biotechnol. 2014; 24: 119-126.

[8] Mun S, Lee J, Lim MK, et al. Development of a novel diagnostic biomarker set for rheumatoid arthritis using a proteomics approach. Biomed Res Int. 2018; 2018: 7490723.

[9] Bhattacharjee M, Sharma R, Goel R, et al. A multi-lectin affinity approach for comparative glycoprotein profiling of rheumatoid arthritis and spondyloarthropathy. Clin Proteomics. 2013; 10: 11.

[10] Brevet P, Lattard C, Guillou C, et al. Anti-carbamylated fibrinogen antibodies might be associated with a specific rheumatoid phenotype and include a subset recognizing in vivo epitopes of its γ chain one of which is not cross reactive with anti-citrullinated protein antibodies. Front Immunol. 2021; 12: 733511.

[11] Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011; 108: 17372-17377.

[12] Kissel T, Reijm S, Slot LM, et al. Antibodies and B cells recognizing citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Ann Rheum Dis. 2020; 79: 472-480.

[13] Li K, Mo W, Wu L, et al. Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2021; 80: 739-747.

[14] Jeong JS, Jiang L, Albino E, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteom. 2012; 11: O111. 016253.

[15] Hu CJ, Pan JB, Song G, et al. Identification of novel biomarkers for Behcet disease diagnosis using human proteome microarray approach. Mol Cell Proteomics. 2017; 16: 147-156.

[16] Hu CJ, Song G, Huang W, et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012; 11: 669-680.

[17] Kokkonen H, Brink M, Hansson M, et al. Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis. Arthritis Res Ther. 2015; 17: 125.

[18] Lu J, Bi Y, Zhu Y, et al. CD3D, GZMK, and KLRB1 are potential markers for early diagnosis of rheumatoid arthritis, especially in anti-citrullinated protein antibody-negative patients. Front Pharmacol. 2021; 12: 726529.

[19] Zhao H, Tang C, Wang M, et al. Ferroptosis as an emerging target in rheumatoid arthritis. Front Immunol. 2023; 14: 1260839.

[20] Chen T, Zhou Z, Peng M, et al. Glutathione peroxidase 3 is a novel clinical diagnostic biomarker and potential therapeutic target for neutrophils in rheumatoid arthritis. Arthritis Res Ther. 2023; 25: 66.

[21] Mulherin DM, Thurnham DI, Situnayake RD. Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis. Ann Rheum Dis. 1996; 55: 837-840.

[22] Arroul-Lammali A, Rahal F, Chetouane R, et al. Ex vivo all-trans retinoic acid modulates NO production and regulates IL-6 effect during rheumatoid arthritis: a study in Algerian patients. Immunopharmacol Immunotoxicol. 2017; 39: 87-96.

[23] Mosquera N, Rodriguez-Trillo A, Blanco FJ, et al. All-trans retinoic acid inhibits migration and invasiveness of rheumatoid fibroblast-like synoviocytes. J Pharmacol Exp Ther. 2020; 372: 185-192.

[24] Zhang Y, Luo Y, Shi J, et al. All-trans retinoic acid alleviates collagen-induced arthritis and promotes intestinal homeostasis. Sci Rep. 2024; 14: 1811.

[25] Ge C, Tong D, Lönnblom E, et al. Antibodies to cartilage oligomeric matrix protein are pathogenic in mice and may be clinically relevant in rheumatoid arthritis. Arthritis Rheumatol. 2022; 74: 961-971.

[26] Ahrman E, Lorenzo P, Holmgren K, et al. Novel cartilage oligomeric matrix protein (COMP) neoepitopes identified in synovial fluids from patients with joint diseases using affinity chromatography and mass spectrometry. J Biol Chem. 2014; 289: 20908-20916.

[27] Lorenzo P, Aspberg A, Saxne T, Önnerfjord P. Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays. Osteoarthritis Cartilage. 2017; 25: 1436-1442.

[28] Smith SC, Folefac VA, Osei DK, Revell PA. An immunocytochemical study of the distribution of proline-4-hydroxylase in normal, osteoarthritic and rheumatoid arthritis synovium at both the light and electron microscopic level. Br J Rheumatol. 1998; 37: 287-291.

[29] Yu R, Zhang J, Zhuo Y, et al. Identification of diagnostic signatures and immune cell infiltration characteristics in rheumatoid arthritis by integrating bioinformatic analysis and machine-learning strategies. Front Immunol. 2021; 12: 724934.

[30] Ni M, Wei W, Wang Y, et al. Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis. J Clin Immunol. 2013; 33: 947-953.

[31] Hashaad NI, Fawzy RM, Elazem AA, Youssef MI. Serum calreticulin as a novel biomarker of juvenile idiopathic arthritis disease activity. Eur J Rheumatol. 2017; 4: 19-23.

[32] Okamoto K, Isohashi F. Purification and primary structure of a macromolecular-translocation inhibitor II of glucocorticoid-receptor binding to nuclei from rat liver. Inhibitor II is the 11.5-kDa Zn2+-binding protein (parathymosin). Eur J Biochem. 2000; 267: 155-162.

[33] Hannappel E, Huff T. Prothymosin alpha, parathymosin, and beta-thymosins: structure and function. Vitam Horm. 2003; 66: 257-296.

[34] Haritos AA, Salvin SB, Blacher R, et al. Parathymosin alpha: a peptide from rat tissues with structural homology to prothymosin alpha. Proc Natl Acad Sci USA. 1985; 82: 1050-1053.

[35] Okamoto K, Isohashi F. Macromolecular translocation inhibitor II (Zn(2+)-binding protein, parathymosin) interacts with the glucocorticoid receptor and enhances transcription in vivo. J Biol Chem. 2005; 280: 36986-36993.

[36] Hirata-Tsuchiya S, Suzuki S, Okamoto K, et al. A small nuclear acidic protein (MTI-II, Zn2+ - binding protein, parathymosin) attenuates TNF-α inhibition of BMP-induced osteogenesis by enhancing accessibility of the Smad4-NF-κB p65 complex to Smad binding element. Mol Cell Biochem. 2020; 469: 133-142.

[37] Auger I, Balandraud N, Rak J, et al. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis. 2009; 68: 591-594.

[38] Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985; 28: 1326-1335.

[39] Ravindran V, Rachapalli S. An overview of commonly used radiographic scoring methods in rheumatoid arthritis clinical trials. Clin Rheumatol. 2011; 30: 1-6.

[40] Kung LA, Tao SC, Qian J, et al. Global analysis of the glycoproteome in Saccharomyces cerevisiae reveals new roles for protein glycosylation in eukaryotes. Mol Syst Biol. 2009; 5: 308.

[41] Liu Q, Chen C, Zhang Y, Hu Z. Feature selection for support vector machines with RBF kernel. Artificial Intelligence Review. 2011; 36: 99-115.

[42] Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011; 12: 2825-2830.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.